Large-scale phenotypic screening and drug data fuel our AI models to identify targets, pathways, and drug compounds needed to change a cell from a diseased to a healthy state.
What does this enable?
Directly optimizing for cellular rejuvenation enables us to use a model-in-the-loop to guide phenotypic screening for unknown/alternate complex disease targets. We leverage drug perturbation data to generate small molecule formulations in conjunction with predicted target data. Modeling the effects of drugs on individual phenotypic data enables precision treatments for patient sub-populations.
We are currently working on methods for oncology, and neurological diseases. In the long term, we aim to use this technology for age-related diseases as well as aging itself.
